Panitumumab (Vectibix) is a monoclonal antibody medication used to treat certain types of colorectal cancer. It is a targeted therapy, meaning it targets specific molecules involved in cancer cell growth and survival. Panitumumab works by blocking the activity of the epidermal growth factor receptor (EGFR), a protein found on the surface of some cancer cells. This prevents the cancer cells from growing and spreading. Panitumumab is usually given in combination with chemotherapy drugs. It is approved for use in patients who have failed other treatments or who have metastatic colorectal cancer that is no longer responding to other treatments.
Panitumumab, sold under the brand name Vectibix, is a medication used to treat a specific type of colorectal cancer [1]. Here's a breakdown of its key aspects:
Type of drug: Panitumumab is a recombinant humanized monoclonal antibody [2]. This means it's a man-made protein engineered to target a specific molecule in the body.
Target: Panitumumab targets the epidermal growth factor receptor (EGFR) [1]. EGFR is a protein found on the surface of some cells that can be involved in cancer cell growth.
Uses: Panitumumab is used to treat metastatic colorectal cancer, which is cancer that has spread from the colon or rectum to other parts of the body [2, 3]. It's typically used for patients whose cancer has not responded to other chemotherapy regimens and whose tumors have a specific genetic feature called "wild-type RAS" [3].
How it works: Panitumumab binds to EGFR, blocking its activity and potentially slowing or stopping the growth of cancer cells [2].
Important note: Panitumumab is not a cure for cancer, but it may help control the disease.
Administration: Panitumumab is given by injection into a vein by a healthcare professional [2].
Side effects: Panitumumab can cause some side effects, including skin reactions, fatigue, diarrhea, and infections [2].